LONDON (Reuters) - Bristol-Myers Squibb’s immunotherapy drug Opdivo has been approved in Europe for the treatment of classical Hodgkin lymphoma, a rare blood cancer, the U.S. company said on Wednesday.
Opdivo is already approved for melanoma, lung cancer and kidney cancer.
Reporting by Ben Hirschler. Editing by Jane Merriman
Our Standards: The Thomson Reuters Trust Principles.